Johnson & Johnson or Amicus Therapeutics, Inc.: Who Manages SG&A Costs Better?

Managing SG&A Costs: A Tale of Two Companies

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Johnson & Johnson, a global healthcare giant, and Amicus Therapeutics, a smaller biotech firm, offer a fascinating contrast in SG&A management from 2014 to 2023.

Johnson & Johnson: A Steady Hand

Over the past decade, Johnson & Johnson has maintained a relatively stable SG&A expense, averaging around $21 billion annually. Despite fluctuations, their expenses have shown a slight downward trend, indicating efficient cost management strategies.

Amicus Therapeutics: Rapid Growth

Conversely, Amicus Therapeutics has seen a dramatic increase in SG&A expenses, growing by over 1,200% from 2014 to 2023. This surge reflects their aggressive expansion and investment in growth.

In conclusion, while Johnson & Johnson exemplifies stability, Amicus Therapeutics showcases dynamic growth, each with its own strategic approach to SG&A management.